Sanjana Mukherjee

Sanjana Mukherjee

Auto-generated profile, based on publicly available information

Sanjana Mukherjee

Present address: Center for Global Health Policy and Politics, Georgetown University, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SMSanjana Mukherjee
Sanjana Mukherjee
RMRebekah E. Mosci
Rebekah E. Mosci
CAChase M. Anderson
Chase M. Anderson
BSBrian A. Snyder
Brian A. Snyder
JCJames Collins
James Collins
SMShannon Manning
Shannon Manning
High frequencies of antimicrobial drug resistance were observed in O157 and non-O157 Shiga toxin–producing E. coli strains recovered from patients in Michigan during 2010–2014. Resistance was more common in non-O157 strains and independently associated with hospitalization, indicating that resistance could contribute to more severe disease outcomes.

1 December 2015 in Bioresource Technology
Verified
Journal Article
Closed access
SSSaurabh Saran
Saurabh Saran
SMSanjana Mukherjee
Sanjana Mukherjee
JDJyotsana Dalal
Jyotsana Dalal
RSRajendra Saxena
Rajendra Saxena

12 January 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SMSanjana Mukherjee
Sanjana Mukherjee
The availability and accessibility of safe and effective drugs, vaccines, and diagnostics are essential to reducing the immense global burden of neglected tropical diseases (NTDs). National regulatory authorities, such as the United States Food and Drug Administration (FDA), play an essential role in this effort to ensure access to safe and effective medical products by working within a set of legal frameworks and regulatory functions. However, medical product development for NTDs remains neglected, as combating NTDs is not a viable commercial market for pharmaceutical companies. To spur research and development (R&D) of NTD products, the US government has authorized various programs and policies to engage pharmaceutical companies, many of which provide FDA with the legal authority to implement NTD programs and pathways. Thus, this review provides a clear overview of the various regulatory pathways and programs employed by the FDA to increase the availability of NTD drugs, vaccines, and diagnostics. The review assesses the available information on various regulatory considerations and their impact on NTD product development as a first step in estimating the importance of such programs. Next, findings related to currently approved NTD products through these programs are discussed. Lastly, gaps in NTD R&D are identified and suggestions on how to address these are presented. The available data shows that while such incentive programs are factored into companies’ decisions to pursue NTD R&D, approved products for NTDs remains vastly insufficient. Most approved products that utilize these NTD regulatory pathways and programs are overwhelmingly for tuberculosis and malaria—both of which are not considered NTDs by the World Health Organization (WHO). Dedicated efforts are needed to facilitate and accelerate NTD product including employing multiple incentive programs, regular assessment of such programs, and leveraging on public–private partnerships.

29 June 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
SMSanjana Mukherjee
Sanjana Mukherjee
KKKanika Kalra
Kanika Kalra
APAlexandra L. Phelan
Alexandra L. Phelan
The COVID-19 pandemic highlighted significant gaps in equitable access to essential medical countermeasures such as vaccines. Manufacturing capacity for pandemic vaccines, therapeutics, and diagnostics is concentrated in too few countries. One of the major hurdles to equitable vaccine distribution was “vaccine nationalism”, countries hoarded vaccines to vaccinate their own populations first which significantly reduced global vaccine supply, leaving significant parts of the world vulnerable to the virus. As part of equitably building global capacity, one proposal to potentially counter vaccine nationalism is to identify small population countries with vaccine manufacturing capacity, as these countries could fulfill their domestic obligations quickly, and then contribute to global vaccine supplies. This cross-sectional study is the first to assesses global vaccine manufacturing capacity and identifies countries with small populations, in each WHO region, with the capacity and capability to manufacture vaccines using various manufacturing platforms. Twelve countries were identified to have both small populations and vaccine manufacturing capacity. 75% of these countries were in the European region; none were identified in the African Region and South-East Asia Region. Six countries have facilities producing subunit vaccines, a platform where existing facilities can be repurposed for COVID-19 vaccine production, while three countries have facilities to produce COVID-19 mRNA vaccines. Although this study identified candidate countries to serve as key vaccine manufacturing hubs for future health emergencies, regional representation is severely limited. Current negotiations to draft a Pandemic Treaty present a unique opportunity to address vaccine nationalism by building regional capacities in small population countries for vaccine research, development, and manufacturing.

28 August 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
SMSanjana Mukherjee
Sanjana Mukherjee
LGLeah Goodman
Leah Goodman